IN VIVO LIPID-LOWERING AND ANTI-ATHEROSCLEROTIC EFFECTS OF SCORPION TURMERIC (CURCUMA RANGJUED) EXTRACT
Main Article Content
Abstract
Dyslipidemia represents an independent risk factor for cardiovascular diseases, contributing to high morbidity, mortality and healthcare costs worldwide. Previous studies have indicated that improving lipid profiles can effectively prevent the onset and progression of atherosclerosis and associated CVD events. To explore alternatives to conventional lipid-lowering drugs, which often have adverse effects, this study evaluated the in vivo lipid-lowering and anti-atherogenic effects of Scorpion Turmeric (Curcuma rangjued) extract.
GERC7, a honey-based emulsion prepared from steam-distilled C. rangjued rhizome extract, was administered to mice with Poloxamer-407 (P-407)-induced endogenous dyslipidemia. GERC7 significantly reduced plasma lipid levels at all tested doses compared to the disease control group, with the optimal effect observed at the highest dose (7.2 mL/kg/day), reducing total cholesterol (TC) and low-density lipoprotein (LDL) by 31% and 43%, respectively. The atherogenic index (AI), increased 4.9-fold in the disease control group compared to normal controls, but declined substantially in GERC7- and atorvastatin-treated groups. The lowest AI was observed at the 7.2 mL/kg dose, consistent with maximal lipid reduction.
These findings demonstrate dose-dependent lipid-lowering and anti-atherosclerotic effects of GERC7, indicating its potential utility as a multi-target natural therapeutic option for dyslipidemia and atherosclerosis management.
Article Details
Keywords
Dyslipidemia, Atherogenic Index, GERC7, Curcuma rangjued, Nghe Bo Cap
References
Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017;3:17093. doi: 10.1038/nrdp.2017.93.
Murray, C. J., & Lopez, A. D. (2013). Measuring the global burden of disease. New England Journal of Medicine, 369(5), 448-457.
Topor-Madry, R. (2020). Repositioning of the global epicentre of non-optimal cholesterol. Nature.
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020). Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. Advanced Drug Delivery Reviews, 159, 4-33.
Lv, S., Yu, H., Liu, X., & Gao, X. (2021). The study on the mechanism of hugan tablets in treating drug-induced liver injury induced by atorvastatin. Frontiers in Pharmacology, 12, 683707.
Defesche, J. C., Gidding, S. S., Harada-Shiba, M., Hegele, R. A., Santos, R. D., & Wierzbicki, A. S. (2017). Familial hypercholesterolaemia. Nature reviews Disease primers, 3(1), 1-20.
Guo, Y. R., & Choung, S. Y. (2017). Germacrone attenuates hyperlipidemia and improves lipid metabolism in high-fat diet-induced obese C57BL/6J mice. Journal of Medicinal Food, 20(1), 46-55.
Xiao, R., Fang, J., Huang, Q., He, G., Ou, X., De, Y., ... & Xiong, T. (2025). The effect and mechanism of Germacrone in ameliorating alcoholic fatty liver by inhibiting Nrf2/Rbp4. Chinese Medicine, 20(1), 77.
Tian, J., Feng, B., & Tian, Z. (2022). The effect of curcumin on lipid profile and glycemic status of patients with type 2 diabetes mellitus: A systematic review and meta‐analysis. Evidence‐Based Complementary and Alternative Medicine, 2022(1), 8278744.